sponsored
PatientsVille.com Logo

PatientsVille

Marcumar Side Effects Poll Results

Our Users Report - Have you experienced Marcumar side effects?

13 user poll responses

Loading...

« go back

Marcumar Common Side Effects

The most commonly reported Marcumar side effects (click to view or check a box to report):

Fatigue (10)
Dyspnoea (9)
Renal Failure Acute (6)
Fall (6)
International Normalised Ratio Increased (5)
Hyperkinesia (5)
Cardiac Failure (5)
Akathisia (5)
Asthenia (5)
Ballismus (5)
Dizziness (4)
Myalgia (4)
Malaise (4)
Hypotension (4)
Rhabdomyolysis (4)
Depression (4)
Prothrombin Time Prolonged (4)
Alanine Aminotransferase Increased (4)
Pneumonia (4)
Renal Failure (4)

➢ More


If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Fatigue (10)
Dyspnoea (9)
Renal Failure Acute (6)
Fall (6)
Asthenia (5)
International Normalised Ratio Increased (5)
Hyperkinesia (5)
Ballismus (5)
Cardiac Failure (5)
Akathisia (5)
Dizziness (4)
Depression (4)
Alanine Aminotransferase Increased (4)
Malaise (4)
Prothrombin Time Prolonged (4)
Pneumonia (4)
Myalgia (4)
Renal Failure (4)
Hypotension (4)
Rhabdomyolysis (4)
Aspartate Aminotransferase Increased (3)
Cough (3)
Gamma-glutamyltransferase Increased (3)
Skin Disorder (3)
Weight Decreased (3)
Apathy (3)
Gastrointestinal Haemorrhage (3)
Atrial Fibrillation (3)
Transaminases Increased (3)
Thrombocytopenia (3)
Pulmonary Embolism (3)
Nausea (3)
Abdominal Discomfort (3)
Bradycardia (3)
Hemiparesis (2)
Arrhythmia (2)
Angina Pectoris (2)
Anaemia (2)
Hypoaesthesia (2)
Epistaxis (2)
Haematoma (2)
Activated Partial Thromboplastin Time Prolonged (2)
Cardiovascular Insufficiency (2)
Blood Bilirubin Increased (2)
Abdominal Pain (2)
Cardiac Arrest (2)
Blood Pressure Increased (2)
Blood Creatinine Increased (2)
Back Pain (2)
Blood Creatine Phosphokinase Increased (2)

➢ More

sponsored

It is very important to keep track of all side effects and discuss them with your doctor. If you think you may have a medical emergency, call your doctor or 911 immediately.


Most drugs have a large list of nonsevere or mild adverse effects which do not rule out continued usage. These effects depend on individual sensitivity, and can include nausea, dizziness, diarrhea, malaise, vomiting, headache, dermatitis, dry mouth, etc. Some can be considered a form of pseudo-allergic reaction, as not all users experience these effects; many users experience none at all.

Up-to-date List of Marcumar Research Studies

Rank Status Study
1 Recruiting A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Condition: Malignant Melanoma, Neoplasms
Interventions: Drug: vemurafenib;   Drug: phenprocoumon
Outcome Measures: Pharmacokinetics of single-dose phenprocoumon under conditions of vemurafenib steady-state exposure: Area under the concentration-time curve (AUC);   Pharmacokinetics of single-dose phenprocoumon under conditions of vemurafenib steady-state exposure: Maximum plasma concentration (Cmax);   Pharmacokinetics of single-dose phenprocoumon under conditions of vemurafenib steady-state exposure: Time to maximum plasma concentration (Tmax);   Pharmacokinetics of single-dose phenprocoumon under conditions of vemurafenib steady-state exposure: Terminal half-life (t1/2);   Pharmacokinetics of single-dose phenprocoumon under conditions of vemurafenib steady-state exposure: Apparent clearance (CL/F);   Safety: Incidence, nature and severity of adverse events (AEs) and serious AEs, graded according to NCI CTCAE Version 4.0
2 Recruiting Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation
Conditions: Coronary Heart Disease;   Atrial Fibrillation;   Acute Coronary Syndrome;   Atherosclerosis
Interventions: Drug: Dabigatran;   Drug: Phenprocoumon
Outcome Measures: ADP induced platelet aggregation;   Platelet function tests;   Coagulation parameters
3 Recruiting Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification
Conditions: Atrial Fibrillation or Pulmonary Embolism;   Need of Long Term Oral Anticoagulation Therapy (OAT);   Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location
Intervention: Drug: Rivaroxaban or Marcumar
Outcome Measures: Progression of coronary and aortic valve calcification (Agatston Score);   Serum chemistry including Matrix Gla Protein (MPG) level changes and Fetuin-A (baseline/ follow up);   Changes in intima-media thickness of carotid artery (IMT) and flow-mediated vasodilation of brachial artery (FMD);   Progression of aortic calcification (aortic Agatston Score);   Changes in ventricular diastolic function parameters as determined by echocardiography (strain/strain-rate imaging)
4 Recruiting Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)
Condition: Pulmonary Embolism
Interventions: Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Phenprocoumon
Outcome Measures: Major bleedings: Intracranial haemorrhage, Gastrointestinal bleeding and Urogenital bleeding;   Drug utilization pattern;   Non-infective liver disease;   Effectiveness outcomes: Deep vein thrombosis and Pulmonary embolism, Ischaemic stroke, Myocardial infarction, Death
5 Recruiting BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies
Condition: Atrial Fibrillation
Interventions: Drug: Phenprocoumon (Marcumar);   Drug: Rivaroxaban (Xarelto, BAY-59 7939)
Outcome Measures: A prescription of patient preferences pattern including 5 attributes for Discret-Choice-Experiment(DCE)-design in patients with atrial fibrillation;   Patient relevant burden/benefit due to anticoagulation using the ACTS-questionnaire
6 Unknown  D-Dimer Guided Oral Anticoagulant Treatment (OAT)
Condition: Deep Venous Thrombosis
Interventions: Drug: Phenprocoumon;   Drug: Warfarin-Natrium
Outcome Measures: Incidence and severity of objectively documented deep vein thrombosis (DVT) and/or pulmonary embolism (PE);   Incidence and severity of signs and symptoms associated with OAT-induced bleeding measured using the World Health Organization (WHO) bleeding scale.
7 Recruiting Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients
Condition: Unsuspected Pulmonary Embolism
Intervention: Drug: Heparin, fondaparinux, vitamin-K antagonists, aspirin
Outcome Measures: Recurrent (symptomatic) vein thromboembolism, including pulmonary embolism and deep vein thrombosis;   Major, clinically relevant non-major bleeding, and minor bleeding
8 Recruiting Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
Conditions: Venous Thromboembolism;   Neoplasms
Interventions: Drug: low molecular weight heparin;   Drug: vitamin K antagonists
Outcome Measures: Symptomatic recurrent VTE, i.e. the composite of recurrent deep venous thrombosis and fatal or non-fatal pulmonary embolism;   All clinically relevant bleeding (i.e. major bleeding and other clinically relevant non-major bleeding);   all-cause mortality
9 Recruiting Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.
Conditions: Aortic Valve Disease;   Heart Valve Prosthesis Implantation;   Anticoagulants
Intervention: Drug: Rivaroxaban
Outcome Measures: All cause mortality;   Number of patients with prosthetic thrombus;   Number of patients with major bleeding;   Number of patients with ischemia;   Number of patients with stroke;   Number of patients with embolism;   Number of patients with myocardial infarction
10 Recruiting Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD
Condition: Cervical Artery Dissection
Interventions: Drug: Acetylsalicylic acid;   Drug: vitamin K-antagonist
Outcome Measures: Cerebrovascular Ischemia, major Hemorrhagic events or Death (CIHD);   New ischemic strokes; new acute DWI lesions; any major extracranial bleeds; any symptomatic intracranial bleeds; any asymptomatic bleeds; any death; any increase in vessel wall hematoma; mRS 0-2; mRS 0-1; any transient ischemic attack (TIA)
11 Recruiting Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation
Conditions: Coronary Artery Disease;   Atrial Fibrillation
Interventions: Drug: 6 weeks;   Drug: 6 months
Outcome Measures: Composite of death, myocardial infarction, definite stent thrombosis, stroke or major bleeding.;   Ischemic complications (composite of cardiac death, myocardial infarction, stent thrombosis or ischemic stroke);   Bleeding complications (Major bleeding)
12 Recruiting Triple vs. Dual Therapy
Conditions: Atrial Fibrillation;   Acute Coronary Syndrome
Interventions: Drug: Ticagrelor + Apixaban + ASA;   Drug: Ticagrelor + Apixaban
Outcome Measures: β-thromboglobulin (β-TG);   Prothrombin fragment F1+2 (F1+2);   Thrombin-Anti-Thrombin (TAT);   D-dimer;   P-selectin

Marcumar Patient Forum